Why founders should question whether venture capital is right for them at all
EU-Startups argues that before pitching or pricing a funding round, founders should first ask whether venture capital is even the right path for their company — a question especially relevant in health technology.
Most advice aimed at startup founders focuses on tactics: how to pitch investors, how to price a funding round, and how to survive due diligence. Far less attention goes to a more basic question — whether raising venture capital is the right choice for a given business in the first place.
This question carries particular weight in health technology. Unlike many other tech sectors, health tech companies typically face much longer sales cycles, since closing deals with hospitals, insurers, or public health bodies tends to take considerably more time than selling to consumers or standard business clients. That reality shapes how quickly a company can hit the growth milestones venture investors usually expect, given that VC funding is built around relatively fast return cycles.
A mismatch with investor expectations
The discussion suggests founders should honestly assess whether their company's growth pace, market size, and sales cycle actually align with what venture capital demands before pursuing a round. Without that alignment, a startup risks ending up under pressure to hit targets that aren't realistic within its industry's natural timeline, simply because that is what its investors expect.
The piece reflects a broader conversation within Europe's startup ecosystem about whether venture capital should be treated as the default funding path. In some cases — particularly in sectors with longer, more complex sales cycles such as health technology — alternative funding approaches may better suit a company's actual growth trajectory.
